Related Experiment Video

Updated: Nov 22, 2025

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
07:46

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Published on: April 3, 2017

25.6K

PTPN2 negatively regulates macrophage inflammation in atherosclerosis

Xiaorong Hu1, Ruisong Ma2, Jianlei Cao1

  • 1Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.

Aging
|January 7, 2021
PubMed

Insights

Protein tyrosine phosphatase non-receptor type 2 (PTPN2) plays a crucial role in inhibiting macrophage inflammation during atherosclerosis. Decreased PTPN2 levels worsen atherosclerosis by promoting inflammatory responses.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Molecular Medicine

Background:

  • Atherosclerosis, a primary cause of cardiovascular disease, is characterized by systemic inflammation.
  • Pro-inflammatory macrophages drive atherosclerosis progression by secreting inflammatory factors.
  • Understanding the mechanisms regulating macrophage inflammation is vital for therapeutic development.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying atherosclerosis.
  • To elucidate the role of Protein tyrosine phosphatase non-receptor type 2 (PTPN2) in atherosclerosis.
  • To identify PTPN2 as a potential therapeutic target for atherosclerosis.

Main Methods:

  • Construction of an APOE knockout (APOE-/-) mice model of atherosclerosis.
  • Analysis of PTPN2 expression in inflammatory conditions.
  • Investigation of PTPN2's effects on macrophage phenotype and inflammatory factor secretion.
  • Mechanistic studies involving p65/p38/STAT3 signaling pathways.
  • In vivo validation of PTPN2's anti-inflammatory effects.

Main Results:

  • PTPN2 expression was significantly reduced in atherosclerotic mice.
  • PTPN2 deficiency promoted M1 macrophage polarization and enhanced secretion of IL-12 and IL-1.
  • PTPN2 deletion promoted cell proliferation, invasion, and metastasis.
  • PTPN2 de-phosphorylated p65/p38/STAT3, thereby inhibiting macrophage inflammation.
  • In vivo experiments confirmed PTPN2's inhibitory effect on the inflammatory response in atherosclerosis.

Conclusions:

  • PTPN2 acts as a negative regulator in the development of atherosclerosis.
  • PTPN2 de-phosphorylation of p65/p38/STAT3 is a key mechanism controlling macrophage inflammation.
  • PTPN2 represents a promising therapeutic target for treating atherosclerosis.

Keywords:
PTPN2atherosclerosisinflammationmacrophage

More Related Videos

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

30.2K
Electroporation-Based CRISPR-Cas9-Mediated Gene Knockout in THP-1 Cells and Single-Cell Clone Isolation09:29

Electroporation-Based CRISPR-Cas9-Mediated Gene Knockout in THP-1 Cells and Single-Cell Clone Isolation

Published on: February 28, 2025

2.4K

Related Concept Videos

Inflammation01:38

Inflammation

Overview
57.9K
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
15.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
136
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K